Australian Penny Stocks With Strong Balance Sheets Worth A Closer Look

Government bond yields in the US and Europe are staying high as investors worry about sticky inflation and firm growth. That keeps money markets restrictive and makes dependable funding harder for many smaller companies. Financially Fit penny stocks can stand out in this setting because you get low share prices along with a focus on balance sheet strength. This article walks through three screened stocks that fit that profile.

The stocks covered below are just a small sample, and the full screen surfaced more than 400 additional companies with equally compelling financial stories that are not included here. To identify and analyze the setups that best fit your own risk and return preferences, head straight to the Financially Fit Penny Stocks screener.

Ora Banda Mining (ASX:OBM)

Overview: Ora Banda Mining is an Australian resources company that explores, develops and operates mineral projects, with a core focus on gold production at its 100% owned Davyhurst Gold Project north west of Kalgoorlie, alongside exposure to nickel, copper and lithium.

Operations: Ora Banda Mining generates all of its A$554 million in revenue from gold production and exploration activities in Australia.

Market Cap: A$2.53 billion

Ora Banda Mining stands out on this screener because it combines strong profitability with a large and growing resource base at Davyhurst. Earnings growth has been very strong, profit margins have widened to over 40% and return on equity sits close to 60%, while the stock trades at a steep discount to one widely followed cash flow valuation. At the same time, high levels of non cash earnings and reliance on external borrowing raise questions about how durable that profit profile is. Recent drilling success and resource updates across Little Gem, Round Dam and other lodes add scale, but investors still need to weigh that growth against funding risk and earnings quality before making a call.

Ora Banda Mining’s strong margins and high return on equity may appear to present a straightforward quality story, yet the combination of non cash earnings and external borrowing raises deeper questions that the 4 key rewards and 1 important major warning sign might answer in an unexpected way

Build your own high margin shortlist

Ora Banda Mining and the two other stocks in this article all came from a single screen, but the real edge is in building filters that fit your own playbook. Use our customisable Screener to combine valuation, quality, balance sheet and risk checks into your own shortlist, or lean on any of our curated Investing Ideas.

Alkane Resources (ASX:ALK)

Overview: Alkane Resources is an Australia based gold producer and explorer with three operating gold and antimony mines across New South Wales, Victoria and Sweden, alongside the large Boda Kaiser gold copper project and minority investments in junior miners.

Market Cap: A$2.10 billion

Alkane Resources catches the eye because it has shifted from a single mine operator into a three mine producer with exposure to gold, antimony and copper, backed by a strong cash position and a large long term development project at Boda Kaiser. Earnings growth over the past year has been very large, margins have strengthened and the stock trades well below some intrinsic value estimates. However, all funding comes from external borrowing and the group now carries higher complexity across multiple underground and higher cost assets. For investors who can handle that mix of execution and balance sheet risk, the combination of cash generation today and optionality at Boda Kaiser makes Alkane a stock that may deserve closer attention.

Alkane Resources appears to be a cash backed, multi mine story that the market may not have fully priced in yet. To see how its underground complexity and Boda Kaiser exposure compare, start with the analysis report for Alkane Resources

Sigma Healthcare (ASX:SIG)

Overview: Sigma Healthcare is an Australian pharmacy group that franchises well known brands such as Chemist Warehouse, Amcal and Discount Drug Stores, while also wholesaling medicines, health products and providing logistics and support services to community pharmacies, including online channels.

Operations: Sigma Healthcare generates about A$9.55b in revenue from its healthcare focused wholesaling, logistics and retail pharmacy support operations, primarily within Australia.

Market Cap: A$34.28b

Sigma Healthcare sits at an interesting crossroads for investors. The core business is tightly linked to everyday healthcare spending, with earnings growing about 31% per year over the past 5 years and earnings quality described as high. However, today investors are paying a rich P/E multiple and current profit margins of 6.3% are down from 11.5%, which leaves less room for execution missteps. Funding is entirely from external borrowing and the board is relatively fresh, which both add uncertainty. Recent decision making around potential Boots acquisition talks also hints at how management is thinking about capital allocation and growth priorities, and that is where the real story starts to become more nuanced.

Sigma Healthcare’s earnings growth and everyday healthcare exposure suggest a stronger story than today’s rich P/E implies. Get the context behind those margins and borrowing choices in the analysis report for Sigma Healthcare

Curious About Alternative Stock Paths?

Fresh stock ideas can move from quiet to breakout quickly. Use these screens before momentum really flies and while the data still matters. Act now.

• Spot companies quietly building strength before momentum takes off by running the 10 resilient stocks with low risk scores and see which businesses still sit under the radar for now.
• Ride potential infrastructure momentum by checking the 38 power grid technology and infrastructure stocks and find companies positioned while demand for grid upgrades is still being priced in.
• Get ahead of the next wave in automation by scanning the 37 robotics and automation stocks and track which stocks are gaining traction before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com